CFP1 is also a promising novel target for developing the new generation DNMT inhibitor based on its functional interaction with DNMT, and the efficiency of DNMT1/CFP1 complex disruption has been displayed in enhancing chemotherapy sensitivity in glioblastoma.46 Given these findings, we propose that CFP1 is a critical epigenetic regulator for LUAD progression and might be a novel epigenetic therapeutic target. The gene discussed is CXXC1; the disease is glioblastoma.